OPK:NASDAQOpko Health, Inc. Analysis

OPKO Health trades at $1.51, barely above its 20‑day SMA of 1.44 and well below the 50‑day SMA of 1.29, indicating a price that is still testing short‑term support at $1.36. Technical momentum is mixed: the RSI sits at 69 (approaching overbought), while the MACD line is marginally above its signal, producing a tiny bullish histogram. Volume is on an increasing trend, yet the 30‑day volatility is a lofty 41.6% and the beta of 0.95 suggests market‑aligned price swings. Fundamentally, the company reports a negative PE (-4.72), a steep revenue decline of ‑17%, and operating margins in the ‑41% range, but its price‑to‑book of 0.95 and upside potential of nearly 190% hint at undervaluation. Recent material news includes an amended partnership with Nicoya Therapeutics that grants OPKO a 15% equity stake and expands commercialization of the Rayaldee product in Greater China, alongside pre‑clinical data from OPKO Biologics presented at ENDO 2026. These developments could unlock future revenue streams, but the company remains cash‑flow negative with a sizable debt load, underscoring the need for cautious optimism.